文献速递艾滋病与性传播感染

法国HIV-1 O组感染的临床特征与抗逆转录病毒免疫病毒学应答

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究纳入101例HIV-1 O组感染患者,用分段线性模型估算cART前后CD4计数,用Kaplan-Meier法分析临床进展和病毒学应答。结果显示诊断后5年进展至C期的累积概率为16.6%,CD4年均下降30.5 cells/μL;cART后12个月CD4平均增加147 cells/μL,89.3%患者中位3.8个月实现pVL<40 copies/mL。

要点

  • HIV-1 O组感染自然病程较M组温和,5年进展至C期累积概率16.6%。
  • cART后12个月CD4平均增加147 cells/μL,89.3%患者中位3.8个月病毒载量<40 copies/mL。
  • 使用非推荐NNRTI方案较boosted PI方案CD4增益少约100 cells/μL。

核心结论

  • HIV-1 O组感染自然进展较HIV-1 M组温和,基于M组指南的当前管理高效。

研究设计与样本

  • 研究纳入101例HIV-1 O组感染患者,采用分段线性模型估算cART前后CD4计数。
  • 采用Kaplan-Meier生存曲线估算ART前达到临床C期时间和cART后达到pVL<40 copies/mL时间。

主要发现

  • 诊断后5年内达到临床C期的累积概率为16.6%,CD4平均年下降30.5 cells/μL。
  • ART初治患者cART后12个月CD4平均增加147 cells/μL,89.3%患者中位3.8个月达到pVL<40 copies/mL。
  • 使用非推荐NNRTI为基础方案较ritonavir-boosted PI为基础方案,1年后CD4增益少约100 cells/μL。
  • 2007年以来随访患者最近一次随访中位CD4计数为498 cells/μL,87%患者pVL<40 copies/mL。

临床怎么用

  • HIV-1 O组感染可参照HIV-1 M组指南进行cART管理,优先选择ritonavir-boosted PI为基础方案。

局限性

  • 需开展HIV-1 M组与O组可比人群研究以确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients. METHODS: Piecewise linear models were used to estimate CD4 count before and after cART initiation. Kaplan-Meier survival curves were used to estimate time to reach clinical stage C before antiretroviral therapy (ART) and to analyze time to achieve a plasma viral load (pVL) <40 copies/mL following cART initiation. Immunovirological response was assessed at the most recent visit in patients on active follow-up. RESULTS: Data showed a 16.6% cumulative probability of reaching stage C within 5 years following diagnosis, and a mean CD4 decrease of -30.5 cells/μL/year. cART initiation in ART-naive patients led to a mean CD4 gain of 147 cells/μL after 12 months, and to a median pVL of <40 copies/mL after 3.8 months for 89.3%. Initiation with a nonrecommended nonnucleoside reverse transcriptase inhibitor-based vs a ritonavir-boosted protease inhibitor-based regimen resulted in a much smaller gain of around 100 CD4 cells/μL after 1 year. Patients on follow-up since 2007 had a median CD4 count of 498 cells/μL, and 87% had a pVL <40 copies/mL at the most recent follow-up visit. CONCLUSIONS: This work provides unique data on HIV-1/O infection, in favor of a milder natural evolution than HIV-1 group M (HIV-1/M) and of a highly efficient current management, based on HIV-1/M guidelines, despite genetic divergence. Studies of comparable HIV-1/M and HIV-1/O populations are needed to confirm these results.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Unal G, Alessandri-Gradt E, Leoz M, et al. Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals. Clin Infect Dis. 2018. PMID: 29272369. doi:10.1093/cid/cix1087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。